Newspatrolling.com News cum Content Syndication Portal Online
Q2FY26 Performance Highlights
- Revenues at ₹3,758 million, up 12% YoY
- EBITDA grew 37% YoY to ₹1,065 million
- EBITDA margin of 28%, an expansion of ~506 bps YoY
- Adjusted PAT stood at ₹449 million with adjusted EPS of ₹3.9
Bangalore, India, November 11, 2025 – OneSource Speciality Pharma Limited (BSE:544292, NSE: ONESOURCE) today announced its consolidated financial results for the quarter ended September 30, 2025 (Q2FY26).
Financial Highlights (In ₹ million)
| Particulars | Q2FY26 | QoQ% | YoY% | H1FY26 | YoY% |
| Revenues | 3,758 | +15% | +12% | 7,030 | +12% |
| EBITDA | 1,065 | +20% | +37% | 1,950 | +37% |
| EBITDA % | 28% | ~130 bps | ~ 506 bps | 28% | ~ 504 bps |
| Adjusted PAT1 | 449 | +21% | Loss to profit | 820 | Loss to profit2 |
| Adjusted EPS (₹)1 | 3.9 | +21% | – | 7.2 | – |
Adjusted PAT and Adjusted EPS excludes exceptional items (Q2FY26: Nil, Q1FY26: ₹29m, Q2FY25: ₹58m) and scheme related intangible amortisation (FY26: ₹344m for each quarter, Q2FY25: ₹357m)- Excludes one-time tax asset recognised (Q1FY25: ₹411m) as a results of the scheme of arrangement.
The recently announced proposed acquisition of Poland and Brooks delivered a strong first half with a combined revenue of $29 million and EBITDA of $11 million, translating into healthy margins of 38%.
Mr. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma Limited speaking on the performance said, “Q2 performance was underpinned by MSAs executions and sales from our IP led base business. DDC capacity addition is being accelerated to support upcoming customer launches. We are excited about recently approved proposed acquisition for multi-dose fill-finish site in Europe and integrated carbapenem facility in India and accordingly are raising our FY28 revenue outlook to $500m+.”
